Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
PLANET II
Randomised, Double-blind, 52-wk, Parallel-grp Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Non-diabetic Patients With Moderate Proteinuria
2 other identifiers
interventional
237
11 countries
107
Brief Summary
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Feb 2006
Typical duration for phase_2
107 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2006
CompletedFirst Submitted
Initial submission to the registry
February 23, 2006
CompletedFirst Posted
Study publicly available on registry
February 27, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2009
CompletedResults Posted
Study results publicly available
December 30, 2010
CompletedJune 16, 2011
June 1, 2011
3.3 years
February 23, 2006
March 22, 2010
June 14, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Urinary Protein/Creatinine Ratio at Week 52 [LOCF]
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Assessed at baseline and Week 52 (LOCF)
Secondary Outcomes (71)
Urinary Protein/Creatinine Ratio at Week 26.
Assessed at baseline and Week 26
Urinary Albumin/Creatinine Ratio at Week 26
Assessed at baseline and Week 26
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
Assessed at baseline and Week 52 [LOCF]
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
Assessed at baseline and Week 26
Change From Baseline in eGFR at Week 52 [LOCF]
Assessed at baseline and Week 52 [LOCF]
- +66 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- greater than or equal to 18 years of age
- Hyperlipidemia
- Urinary protein
You may not qualify if:
- Previous rosuvastatin treatment \< 6 months prior to Visit 1
- Statin intolerance
- Severe hypertension
- Diabetes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (107)
Research Site
Avondale, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Pasadena, California, United States
Research Site
Riverside, California, United States
Research Site
Clearwater, Florida, United States
Research Site
Hollywood, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Augusta, Georgia, United States
Research Site
Topeka, Kansas, United States
Research Site
Columbia, Maryland, United States
Research Site
Springfield, Massachusetts, United States
Research Site
Detroit, Michigan, United States
Research Site
Columbia, Missouri, United States
Research Site
Orchard Park, New York, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Columbia, South Carolina, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Richmond, Virginia, United States
Research Site
Gig Harbor, Washington, United States
Research Site
Milwaukee, Wisconsin, United States
Research Site
Curitiba, Paraná, Brazil
Research Site
São Paulo, São Paulo, Brazil
Research Site
Blagoevgrad, Bulgaria
Research Site
Burgas, Bulgaria
Research Site
Gabrovo, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Vancouver, British Columbia, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
Courtice, Ontario, Canada
Research Site
East York, Ontario, Canada
Research Site
Oakville, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Richmond Hill, Ontario, Canada
Research Site
Scarborough Village, Ontario, Canada
Research Site
Thunder Bay, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Copenhagen, Denmark
Research Site
Fredericia, Denmark
Research Site
Herlev, Denmark
Research Site
Holbæk, Denmark
Research Site
Roskilde, Denmark
Research Site
Viborg, Denmark
Research Site
Berlin, Germany
Research Site
Cloppenburg, Germany
Research Site
Demmin, Germany
Research Site
Düsseldorf, Germany
Research Site
Elsenfeld, Germany
Research Site
Göttingen, Germany
Research Site
Hanover, Germany
Research Site
Würzburg, Germany
Research Site
Ajka, Hungary
Research Site
Baja, Hungary
Research Site
Balatonfüred, Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Eger, Hungary
Research Site
Gyula, Hungary
Research Site
Gy�r, Hungary
Research Site
Keszthely, Hungary
Research Site
Miskolc, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Szolnok, Hungary
Research Site
Szombathely, Hungary
Research Site
Zalaegerszeg, Hungary
Research Site
Bergamo, BG, Italy
Research Site
Bologna, BO, Italy
Research Site
Brescia, BS, Italy
Research Site
Acireale, CT, Italy
Research Site
Foggia, FG, Italy
Research Site
Florence, FI, Italy
Research Site
Parma, PR, Italy
Research Site
Reggio Calabria, RC, Italy
Research Site
Sassari, SS, Italy
Research Site
Teramo, TE, Italy
Research Site
Torino, TO, Italy
Research Site
Castelfranco Veneto, TV, Italy
Research Site
Treviso, TV, Italy
Research Site
Mestre, VE, Italy
Research Site
Zapopan, Jalisco, Mexico
Research Site
Mexico City, Mexico City, Mexico
Research Site
D.F, Mexico, Mexico
Research Site
San Luis Potos�, Mexico, Mexico
Research Site
Cuernavaca, Morelos, Mexico
Research Site
Aguascalientes, Mexico
Research Site
Durango, Mexico
Research Site
Brasov, Brașov County, Romania
Research Site
Cluj-Napoca, Cluj, Romania
Research Site
Constanța, Constanța County, Romania
Research Site
Suceava, Suceava, Romania
Research Site
Timișoara, Timiș County, Romania
Research Site
Bucharest, Romania
Research Site
Craiova, Romania
Research Site
Iași, Romania
Research Site
Johannesburg, Gauteng, South Africa
Research Site
Pretoria, South Africa, South Africa
Research Site
Parow, W Cape, South Africa
Research Site
Cape Town, South Africa
Research Site
Durban, South Africa
Related Publications (2)
Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
PMID: 38018702DERIVEDde Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90. doi: 10.1016/S2213-8587(14)70246-3. Epub 2015 Feb 4.
PMID: 25660356DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Gerard Lynch
- Organization
- AstraZeneca
Study Officials
- STUDY DIRECTOR
AstraZeneca Crestor Medical Science Director, MD
AstraZeneca
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- LTE60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
February 23, 2006
First Posted
February 27, 2006
Study Start
February 1, 2006
Primary Completion
June 1, 2009
Study Completion
June 1, 2009
Last Updated
June 16, 2011
Results First Posted
December 30, 2010
Record last verified: 2011-06